Effect of JKB-122 on Prednisolone and Azathioprine Induced Remission in Autoimmune Hepatitis (AIH)
Status:
Not yet recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2 study. All patients will receive prednisolone and AZA as standard of care
(SOC) during the study. At the end of the study, all data collected will be analyzed the
efficacy and safety of JKB-122 on SOC reduction and inflammation improvement in Autoimmune
Hepatitis